Abeona Therapeutics Inc (NASDAQ:ABEO) Director Sells $20,400.00 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $5.10, for a total value of $20,400.00. Following the completion of the transaction, the director now owns 68,334 shares of the company’s stock, valued at approximately $348,503.40. This represents a 5.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Abeona Therapeutics Trading Down 0.6 %

Shares of ABEO opened at $5.19 on Wednesday. Abeona Therapeutics Inc has a 1-year low of $3.05 and a 1-year high of $9.01. The company has a market capitalization of $225.61 million, a P/E ratio of -1.93 and a beta of 1.46. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm’s 50 day simple moving average is $5.81 and its 200 day simple moving average is $5.72.

Institutional Trading of Abeona Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its stake in Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after acquiring an additional 429,456 shares during the last quarter. abrdn plc increased its position in shares of Abeona Therapeutics by 158.8% during the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares during the last quarter. Western Standard LLC raised its holdings in shares of Abeona Therapeutics by 7.0% during the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after buying an additional 110,998 shares in the last quarter. Geode Capital Management LLC lifted its position in Abeona Therapeutics by 21.7% in the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after buying an additional 83,050 shares during the last quarter. Finally, Rosalind Advisors Inc. boosted its stake in Abeona Therapeutics by 4.7% in the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after buying an additional 82,000 shares in the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on ABEO shares. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Monday, November 25th. StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 9th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.